Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Prime Medicine, Inc. Common Stock (PRME)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/07/2025: PRME (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.14% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 184.94M USD | Price to earnings Ratio - | 1Y Target Price 13.1 |
Price to earnings Ratio - | 1Y Target Price 13.1 | ||
Volume (30-day avg) 1498766 | Beta 1.89 | 52 Weeks Range 1.26 - 8.27 | Updated Date 04/6/2025 |
52 Weeks Range 1.26 - 8.27 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2025.74% |
Management Effectiveness
Return on Assets (TTM) -51.51% | Return on Equity (TTM) -136.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35288787 | Price to Sales(TTM) 62 |
Enterprise Value 35288787 | Price to Sales(TTM) 62 | ||
Enterprise Value to Revenue 11.83 | Enterprise Value to EBITDA -3.1 | Shares Outstanding 131161000 | Shares Floating 60638823 |
Shares Outstanding 131161000 | Shares Floating 60638823 | ||
Percent Insiders 23.91 | Percent Institutions 59.07 |
Analyst Ratings
Rating 4.5 | Target Price 13.7 | Buy 4 | Strong Buy 7 |
Buy 4 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Prime Medicine, Inc. Common Stock
Company Overview
History and Background
Prime Medicine, Inc. was founded in 2020, focusing on developing prime editing, a versatile gene editing technology. It went public in 2022. The company is still in the early stages of development and pre-revenue.
Core Business Areas
- Gene Editing Therapeutics: Prime Medicine is dedicated to creating potentially curative gene editing therapies using its prime editing technology across a range of diseases.
Leadership and Structure
Keith Gottesdiener is the CEO. The company has a management team focused on research, development, and business operations. The organizational structure supports its research-driven focus.
Top Products and Market Share
Key Offerings
- Prime Editing Technology: Prime editing is Prime Medicine's core technology, aimed at precisely correcting genetic defects. It is currently in pre-clinical development. Competitors include companies using CRISPR-Cas9 and other gene editing technologies such as Beam Therapeutics (BEAM) and Editas Medicine (EDIT).
Market Dynamics
Industry Overview
The gene editing industry is rapidly evolving, with significant potential for treating genetic diseases. However, it also faces regulatory hurdles and challenges related to safety and efficacy.
Positioning
Prime Medicine is positioned as a leader in prime editing technology. Its competitive advantage lies in the precision and versatility of its prime editing approach, which addresses limitations of previous gene editing methods.
Total Addressable Market (TAM)
The TAM for gene editing therapies is estimated to be in the tens of billions of dollars. Prime Medicine is positioned to capture a significant portion of this market if its technology proves successful and scalable.
Upturn SWOT Analysis
Strengths
- Novel prime editing technology
- Strong intellectual property position
- Experienced leadership team
- Potential for precise and versatile gene editing
Weaknesses
- Early stage of development
- High cash burn rate
- Dependence on a single technology
- Unproven clinical efficacy
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of pipeline into new disease areas
- Advancements in delivery technologies
- Regulatory approvals for prime editing therapies
Threats
- Competition from other gene editing technologies
- Regulatory setbacks
- Clinical trial failures
- Ethical concerns surrounding gene editing
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
- NTLA
Competitive Landscape
Prime Medicine's prime editing technology distinguishes it, but it faces intense competition from established gene editing companies. Success depends on demonstrating superior efficacy and safety.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the progression of its pre-clinical programs and expansion of its intellectual property portfolio.
Future Projections: Future growth is contingent on successful clinical trials and regulatory approvals. Analyst estimates vary depending on the perceived potential of prime editing.
Recent Initiatives: Recent initiatives include advancing lead programs towards clinical trials and securing partnerships to expand its platform.
Summary
Prime Medicine is a high-risk, high-reward biotech company focused on prime editing. Its strength lies in its novel technology and experienced team. However, it faces significant challenges in clinical development, competition, and regulatory hurdles. Success depends on demonstrating the efficacy and safety of its prime editing technology.
Similar Companies
BEAM
Beam Therapeutics Inc
BEAM
Beam Therapeutics Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
NTLA
Intellia Therapeutics Inc
NTLA
Intellia Therapeutics Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and results are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prime Medicine, Inc. Common Stock
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2022-10-20 | President, CEO, Secretary & Director Dr. Keith Michael Gottesdiener M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 214 | Website https://primemedicine.com |
Full time employees 214 | Website https://primemedicine.com | ||
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.